{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:09:38Z","timestamp":1779894578237,"version":"3.53.1"},"reference-count":72,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Background: Impulse control disorders (ICDs) are a common non-motor complication in Parkinson\u2019s disease (PD) patients with multiple negative consequences for the individual and caregivers. Although ICDs are strongly linked to dopaminergic therapy, particularly dopamine agonists, only a percentage of patients develop these behaviors, suggesting the involvement of additional susceptibility factors, including genetic variability. This review aims to analyze current knowledge on the genetic background of ICDs. Methods: A literature search was conducted in the PubMed and Scopus databases for peer-reviewed research regarding the role of genetics in ICDs, published in the English language from 1996 to 2026. References of the selected articles for possible additional articles were also screened in order to include most of the key recent evidence. Genes that are involved in the dopaminergic system play a central role in ICD susceptibility, although the findings in studies are often inconsistent and not replicated. Moreover, variants in genes related to the glutamatergic (e.g., GRIN2B), serotonergic (e.g., HTR2A and TPH2), and opioid systems (e.g., OPRK1 and OPRM1) have been implicated, supporting a multi-system contribution to ICD pathophysiology. Conclusions: Early recognition of genetic factors that increase susceptibility to ICDs in PD patients is awaited to increase diagnostic accuracy and expedite individualized treatment.<\/jats:p>","DOI":"10.3390\/life16060897","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:36:56Z","timestamp":1779892616000},"page":"897","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pathways and Genetic Determinants of Impulse Control Disorders in Parkinson\u2019s Disease"],"prefix":"10.3390","volume":"16","author":[{"given":"Kallirhoe","family":"Kalinderi","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Health Sciences, International Hellenic University, 57400 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Papaliagkas","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Health Sciences, International Hellenic University, 57400 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oraiozili","family":"Goula","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 57400 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana","family":"Fidani","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Biology-Genetics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 57400 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2101-4546","authenticated-orcid":false,"given":"Maria","family":"Chatzidimitriou","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Health Sciences, International Hellenic University, 57400 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson\u2019s disease","volume":"5","author":"Breteler","year":"2006","journal-title":"Lancet Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/j.1742-1241.2011.02793.x","article-title":"Pharmacological treatment and the prospect of pharmacogenetics in Parkinson\u2019s disease","volume":"65","author":"Kalinderi","year":"2011","journal-title":"Int. J. Clin. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"105922","DOI":"10.1016\/j.parkreldis.2023.105922","article-title":"Current genetic data on depression and anxiety in Parkinson\u2019s disease patients","volume":"118","author":"Kalinderi","year":"2024","journal-title":"Park. Relat. Disord."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Kalinderi, K., Papaliagkas, V., and Fidani, L. (2024). The Genetic Landscape of Sleep Disorders in Parkinson\u2019s Disease. Diagnostics, 14.","DOI":"10.3390\/diagnostics14010106"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s00415-024-12865-5","article-title":"Impulse control disorders in Parkinson\u2019s disease: What\u2019s new?","volume":"272","author":"Marques","year":"2025","journal-title":"J. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Zhang, J.F., Wang, X.X., Feng, Y., Fekete, R., Jankovic, J., and Wu, Y.C. (2021). Impulse Control Disorders in Parkinson\u2019s Disease: Epidemiology, Pathogenesis and Therapeutic Strategies. Front. Psychiatry, 12.","DOI":"10.3389\/fpsyt.2021.635494"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Molde, H., Moussavi, Y., Kopperud, S.T., Erga, A.H., Hansen, A.L., and Pallesen, S. (2018). Impulse-Control Disorders in Parkinson\u2019s Disease: A Meta-Analysis and Review of Case-Control Studies. Front. Neurol., 9.","DOI":"10.3389\/fneur.2018.00330"},{"key":"ref_8","first-page":"1213393","article-title":"Neuropsychiatric Symptoms in Clinically Defined Parkinson\u2019s Disease: An Updated Review of Literature","volume":"2022","author":"Sanmartino","year":"2022","journal-title":"Behav. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/sj.mp.4000207","article-title":"Studies of the potential role of the dopamine D1 receptor gene in addictive behaviors","volume":"2","author":"Comings","year":"1997","journal-title":"Mol. Psychiatry"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Zainal Abidin, S., Tan, E.L., Chan, S.C., Jaafar, A., Lee, A.X., Abd Hamid, M.H., Abdul Murad, N.A., Pakarul Razy, N.F., Azmin, S., and Ahmad Annuar, A. (2015). DRD and GRIN2B polymorphisms and their association with the development of impulse control behaviour among Malaysian Parkinson\u2019s disease patients. BMC Neurol., 15.","DOI":"10.1186\/s12883-015-0316-2"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Erga, A.H., Dalen, I., Ushakovam, A., Chungm, J., Tzoulis, C., Tysnes, O.B., Alves, G., Pedersen, K.F., and Maple-Gr\u00f8dem, J. (2018). Dopaminergic and Opioid Pathways Associated with Impulse Control Disorders in Parkinson\u2019s Disease. Front. Neurol., 9.","DOI":"10.3389\/fneur.2018.00109"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/humu.20039","article-title":"Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1","volume":"23","author":"Neville","year":"2004","journal-title":"Hum. Mutat."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Fedosova, A., Titova, N., Kokaeva, Z., Shipilova, N., Katunina, E., and Klimov, E. (2021). Genetic Markers as Risk Factors for the Development of Impulsive-Compulsive Behaviors in Patients with Parkinson\u2019s Disease Receiving Dopaminergic Therapy. J. Pers. Med., 11.","DOI":"10.3390\/jpm11121321"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/mdc3.12631","article-title":"Dopamine receptor D3 rs6280 is associated with aberrant decision-making in Parkinson\u2019s disease","volume":"5","author":"Rajan","year":"2018","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/acn3.52111","article-title":"DRD4 gene polymorphism and impulse control disorder induced by dopamine agonists in Parkinson\u2019s disease","volume":"11","author":"Torres","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/ene.14590","article-title":"Integrating genetic and clinical data to predict impulse control disorders in Parkinson\u2019s disease","volume":"28","author":"Adarmes","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/jnnp-2015-312848","article-title":"Clinicalgenetic model predicts incident impulse control disorders in Parkinson\u2019s disease","volume":"87","author":"Kraemmer","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12974-019-1439-y","article-title":"Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson\u2019s disease","volume":"16","author":"Flisar","year":"2019","journal-title":"J. Neuroinflamm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/mds.22678","article-title":"Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson\u2019s disease","volume":"24","author":"Lee","year":"2009","journal-title":"Mov. Disord."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.parkreldis.2011.08.009","article-title":"Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinson\u2019s disease","volume":"18","author":"Lee","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Verholleman, A., Victorri-Vigneau, C., Laforgue, E., Derkinderen, P., Verstuyft, C., and Grall-Bronnec, M. (2020). Naltrexone Use in Treating Hypersexuality Induced by Dopamine Replacement Therapy: Impact of OPRM1 A\/G Polymorphism on Its Effectiveness. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21083002"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e13720","DOI":"10.1111\/cts.13720","article-title":"Comprehensive analysis of clinical and biological features in Parkinson\u2019s disease associated with the LRRK2 G2019S mutation: Data from the PPMI study","volume":"17","author":"Sun","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1601-183X.2011.00758.x","article-title":"Deletion of alpha-synuclein decreases impulsivity in mice","volume":"11","author":"Buchman","year":"2012","journal-title":"Genes Brain Behav."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.14802\/jmd.20026","article-title":"Young-Onset Parkinson\u2019s Disease with Impulse Control Disorder Due to Novel Variants of F-Box Only Protein 7","volume":"13","author":"Yoo","year":"2020","journal-title":"J. Mov. Disord."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"117291","DOI":"10.1016\/j.jns.2020.117291","article-title":"Impulse control behavior in GBA-mutated parkinsonian patients","volume":"421","author":"Amami","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Chen, L., He, X., Mao, L., and Liu, P. (2024). APOE contributes to longitudinal impulse control disorders progression in Parkinson\u2019s disease. BMC Psychiatry, 24.","DOI":"10.1186\/s12888-024-06084-5"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/ijnp\/pyaa028","article-title":"Clinical and Clinical-Pharmacogenetic Models for Prediction of the Most Common Psychiatric Complications Due to Dopaminergic Treatment in Parkinson\u2019s Disease","volume":"23","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-3-030-81147-1_4","article-title":"The Brain\u2019s Reward System in Health and Disease","volume":"1344","author":"Lewis","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0165-6147(92)90025-2","article-title":"Molecular biology of dopamine receptors","volume":"13","author":"Sibley","year":"1992","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_30","first-page":"1133","article-title":"Association of dopamine D1 receptor gene polymorphism with schizophrenia: A meta-analysis","volume":"10","author":"Pan","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/ahg.12104","article-title":"Overlapping dopaminergic pathway genetic susceptibility to heroin and cocaine addictions in African Americans","volume":"79","author":"Levran","year":"2015","journal-title":"Ann. Hum. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"14002","DOI":"10.1038\/npjschz.2014.2","article-title":"The relationship between dopamine receptor D1 and cognitive performance","volume":"1","author":"Tsang","year":"2015","journal-title":"npj Schizophr."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/sj.mp.4000532","article-title":"Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers","volume":"4","author":"Jonsson","year":"1999","journal-title":"Mol. Psychiatry"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.mp.4000350","article-title":"The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability inhealthy volunteers","volume":"3","author":"Pohjalainen","year":"1998","journal-title":"Mol. Psychiatry"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1034\/j.1399-0004.2001.600204.x","article-title":"The additive effect of neurotransmitter genes in pathological gambling","volume":"60","author":"Comings","year":"2001","journal-title":"Clin. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/sj.mp.4002086","article-title":"Genetic variation in components of dopamine neurotransmission impacts ventral striatal reactivity associated with impulsivity","volume":"14","author":"Forbes","year":"2009","journal-title":"Mol. Psychiatry"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/nn1583","article-title":"Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction","volume":"8","author":"Kreek","year":"2005","journal-title":"Nat. Neurosci."},{"key":"ref_38","first-page":"P05","article-title":"Comparison of DRD2, DRD3 and NMDA receptor genotype polymorphisms in Parkinson\u2019s patients and controls","volume":"80","author":"Hassan","year":"2013","journal-title":"Neurology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.parkreldis.2011.10.019","article-title":"Role of genetic polymorphisms of the dopaminergic system in Parkinson\u2019s disease patients with impulse control disorders","volume":"18","author":"Vallelunga","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e01008","DOI":"10.1002\/brb3.1008","article-title":"Taq1A polymorphism and medication effects on inhibitory action control in Parkinson disease","volume":"8","author":"McDonell","year":"2018","journal-title":"Brain Behav."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/mds.24023","article-title":"Questionnaire for impulsive-compulsive disorders in Parkinson\u2019s Disease\u2013Rating Scale","volume":"27","author":"Weintraub","year":"2012","journal-title":"Mov. Disord."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.parkreldis.2018.01.010","article-title":"Behavioral addictions in early-onset Parkinson disease are associated with DRD3 variants","volume":"49","author":"Vela","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.parkreldis.2016.06.005","article-title":"Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson\u2019s disease patients","volume":"30","author":"Krishnamoorthy","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41531-021-00253-z","article-title":"Unlucky punches: The vulnerability-stress model for the development of impulse control disorders in Parkinson\u2019s disease","volume":"7","author":"Theis","year":"2021","journal-title":"npj Park. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Muda, R., Kicia, M., Michalak-Wojnowska, M., Ginszt, M., Filip, A., Gawda, P., and Majcher, P. (2018). The dopamine receptor d4 gene (Drd4) and financial risk taking: Stimulating and instrumental risk-taking propensity and motivation to engage in investment activity. Front. Behav. Neurosci., 12.","DOI":"10.3389\/fnbeh.2018.00034"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.biopsych.2009.09.021","article-title":"Dopamine receptor D4 polymorphism predicts the effect of L-DOPA on gambling behavior","volume":"67","author":"Eisenegger","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Doi Ferre, S., Belcher, A.M., Bonaventura, J., Quiroz, C., S\u00e1nchez-Soto, M., Casad\u00f3-Anguera, V., Cai, N.S., Moreno, E., Boateng, C.A., and Keck, T.M. (2022). Functional and pharmacological role of the dopamine D4 receptor and its polymorphic variants. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1014678"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.5604\/17322693.1227773","article-title":"Molecular characteristic and physiological role of DOPA-decarboxylase","volume":"70","author":"Guenter","year":"2016","journal-title":"Postep. Hig. Med. Dosw."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1124\/dmd.121.000702","article-title":"Emerging Roles of the Human Solute Carrier 22 Family","volume":"50","author":"Yee","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00702-012-0930-8","article-title":"Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson\u2019s disease","volume":"120","author":"Toldi","year":"2013","journal-title":"J. Neural. Transm."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev.med.60.042307.110802","article-title":"The expanded biology of serotonin","volume":"60","author":"Berger","year":"2009","journal-title":"Annu. Rev. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1177\/0269881117725915","article-title":"Serotonin and brain function: A tale of two receptors","volume":"31","author":"Nutt","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/jnr.10173","article-title":"Differential expression of the \u201cC\u201d and \u201cT\u201d alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics","volume":"67","author":"Polesskaya","year":"2002","journal-title":"J. Neurosci. Res."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Latsko, M.S., Gilman, T.L., Matt, L.M., Nylocks, K.M., Coifman, K.G., and Jasnow, A.M. (2016). A Novel Interaction between Tryptophan Hydroxylase 2 (TPH2) Gene Polymorphism (rs4570625) and BDNF Val66Met Predicts a High-Risk Emotional Phenotype in Healthy Subjects. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0162585"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.parkreldis.2016.05.017","article-title":"Tryptophan hydroxylase type 2 variants modulate severity and outcome of addictive behaviors in Parkinson\u2019s disease","volume":"29","author":"Cilia","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev-med-062613-093100","article-title":"Opioid Receptors","volume":"67","author":"Stein","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1002\/mco2.148","article-title":"Mechanism of opioid addiction and its intervention therapy: Focusing on the reward circuitry and mu-opioid receptor","volume":"3","author":"Zhang","year":"2022","journal-title":"MedComm"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pbb.2013.10.018","article-title":"Pharmacogenetics of OPRM1","volume":"123","author":"Crist","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e00660-20","DOI":"10.1128\/MCB.00660-20","article-title":"The Cell Biology of LRRK2 in Parkinson\u2019s Disease","volume":"41","author":"Usmani","year":"2021","journal-title":"Mol. Cell. Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.mrrev.2018.10.001","article-title":"Pathophysiological mechanisms linking F-box only protein 7 (FBXO7) and Parkinson\u2019s disease (PD)","volume":"778","author":"Zhou","year":"2018","journal-title":"Mutat. Res. Rev. Mutat. Res."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Smith, L., and Schapira, A.H.V. (2022). GBA Variants and Parkinson Disease: Mechanisms and Treatments. Cells, 11.","DOI":"10.3390\/cells11081261"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/mds.27989","article-title":"Parkinson\u2019s Progression Markers Initiative Investigators. Clinical and dopamine transporter imaging characteristics of leucine- rich repeat kinase 2 (LRRK2) and glucosylceramidase beta (GBA) Parkinson\u2019s disease participants in the Parkinson\u2019s progression markers initiative: A cross-sectional study","volume":"35","author":"Simuni","year":"2020","journal-title":"Mov. Disord."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/mds.28195","article-title":"ITA-GENE-PD Study Group. GBA-related Parkinson\u2019s disease: Dissection of genotype\u2013phenotype correlates in a large Italian cohort","volume":"35","author":"Petrucci","year":"2020","journal-title":"Mov. Disord."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/jnnp-2017-317348","article-title":"PRoBaND clinical consortium. Features of GBA-associated Parkinson\u2019s disease at presentation in the UK tracking Parkinson\u2019s study","volume":"89","author":"Malek","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Jes\u00fas, S., Huertas, I., Bernal-Bernal, I., Bonilla-Toribio, M., C\u00e1ceres-Redondo, M.T., Vargas-Gonz\u00e1lez, L., G\u00f3mez-Llamas, M., Carrillo, F., Calder\u00f3n, E., and Carballo, M. (2016). GBA variants influence motor and non-motor features of Parkinson\u2019s disease. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0167749"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s00221-017-4941-4","article-title":"Apolipoprotein E: The resilience gene","volume":"235","author":"James","year":"2017","journal-title":"Exp. Brain Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41582-020-0335-5","article-title":"APOE(*)epsilon4 promotes synucleinopathy","volume":"16","author":"Fyfe","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41582-019-0228-7","article-title":"Apolipoprotein E and Alzheimer disease: Pathobiology and targeting strategies","volume":"15","author":"Yamazaki","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.jocn.2011.03.015","article-title":"Association of brain-derived neurotrophic factor (BDNF) Val66Met polymorphism with Parkinson\u2019s disease in a Greek population","volume":"18","author":"Karakasis","year":"2011","journal-title":"J. Clin. Neurosci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/08039488.2016.1240230","article-title":"Neuronal nitric oxide synthase polymorphisms in obsessive-compulsive disorder","volume":"71","author":"Topaloglu","year":"2017","journal-title":"Nord. J. Psychiatry"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Scanferla, L., and Djamshidian, A. (2026). Neuropsychological aspects of impulse control disorders in Parkinson\u2019s disease. Front. Aging Neurosci., 18.","DOI":"10.3389\/fnagi.2026.1768251"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.avb.2008.06.003","article-title":"Role of Serotonin and Dopamine System Interactions in the Neurobiology of Impulsive Aggression and its Comorbidity with other Clinical Disorders","volume":"13","author":"Seo","year":"2008","journal-title":"Aggress. Violent Behav."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/6\/897\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:48:55Z","timestamp":1779893335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/6\/897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":72,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["life16060897"],"URL":"https:\/\/doi.org\/10.3390\/life16060897","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]}}}